Company profile
BRISTOL MYERS SQUIBB CO
NYSE:BMYBiotechnology: Pharmaceutical Preparations
Drug pipeline (334)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ELIQUIS | approved | $4.5BQ2 2026 | 29 | approved |
| OPDIVO | approved | $2.7BQ2 2026 | 222 | approved |
| OPDIVO | approved | $2.7BQ2 2026 | 222 | approved |
| ORENCIA | approved | $1.0BQ2 2026 | 53 | approved |
| ORENCIA | approved | $1.0BQ2 2026 | 53 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (1727)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01733875 | phase1 | completed | 2012-11-01 | 2013-10-09 | Celgene | 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects |
| NCT02034773 | phase1 | completed | 2013-05-01 | 2013-12-01 | Celgene Corporation | 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule |
| NCT02323594 | phase1 | completed | 2014-12-01 | 2015-02-01 | Bristol-Myers Squibb | A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir |
| NCT02156076 | phase2 | terminated | 2014-07-25 | 2016-06-01 | Bristol-Myers Squibb | A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation |
| NCT04151563 | phase1_2 | withdrawn | 2021-04-15 | 2023-12-17 | Bristol-Myers Squibb | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy |
FDA applications (248)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 221075 | 2026-08-13 | NDA | BRISTOL MYERS SQUIBB CO | |||||
Loading… | ||||||||
| NDA 220073 | 2025-04-17 | NDA | BRISTOL MYERS SQUIBB CO | |||||
Loading… | ||||||||
| BLA 761381 | 2024-12-27 | BLA | BRISTOL-MYERS SQUIBB COMPANY | |||||
Loading… | ||||||||
| NDA 216158 | 2024-09-26 | NDA | BRISTOL-MYERS SQUIBB CO | |||||
Loading… | ||||||||
| NDA 218213 | 2023-11-15 | NDA | BRISTOL MYERS SQUIBB CO | |||||
Loading… | ||||||||